228 related articles for article (PubMed ID: 24769065)
1. Mannose derivative and lipid A dually decorated cationic liposomes as an effective cold chain free oral mucosal vaccine adjuvant-delivery system.
Wang N; Wang T; Zhang M; Chen R; Niu R; Deng Y
Eur J Pharm Biopharm; 2014 Sep; 88(1):194-206. PubMed ID: 24769065
[TBL] [Abstract][Full Text] [Related]
2. Using procedure of emulsification-lyophilization to form lipid A-incorporating cochleates as an effective oral mucosal vaccine adjuvant-delivery system (VADS).
Wang N; Wang T; Zhang M; Chen R; Deng Y
Int J Pharm; 2014 Jul; 468(1-2):39-49. PubMed ID: 24704308
[TBL] [Abstract][Full Text] [Related]
3. Multifunctional liposomes constituting microneedles induced robust systemic and mucosal immunoresponses against the loaded antigens via oral mucosal vaccination.
Zhen Y; Wang N; Gao Z; Ma X; Wei B; Deng Y; Wang T
Vaccine; 2015 Aug; 33(35):4330-40. PubMed ID: 25858854
[TBL] [Abstract][Full Text] [Related]
4. Mannosylated and lipid A-incorporating cationic liposomes constituting microneedle arrays as an effective oral mucosal HBV vaccine applicable in the controlled temperature chain.
Wang T; Zhen Y; Ma X; Wei B; Li S; Wang N
Colloids Surf B Biointerfaces; 2015 Feb; 126():520-30. PubMed ID: 25612819
[TBL] [Abstract][Full Text] [Related]
5. Preparation of Multifunctional Liposomes as a Stable Vaccine Delivery-Adjuvant System by Procedure of Emulsification-Lyophilization.
Wang N; Wang T
Methods Mol Biol; 2016; 1404():635-649. PubMed ID: 27076327
[TBL] [Abstract][Full Text] [Related]
6. Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers.
Vandepapelière P; Horsmans Y; Moris P; Van Mechelen M; Janssens M; Koutsoukos M; Van Belle P; Clement F; Hanon E; Wettendorff M; Garçon N; Leroux-Roels G
Vaccine; 2008 Mar; 26(10):1375-86. PubMed ID: 18272264
[TBL] [Abstract][Full Text] [Related]
7. Combining different types of multifunctional liposomes loaded with ammonium bicarbonate to fabricate microneedle arrays as a vaginal mucosal vaccine adjuvant-dual delivery system (VADDS).
Wang N; Zhen Y; Jin Y; Wang X; Li N; Jiang S; Wang T
J Control Release; 2017 Jan; 246():12-29. PubMed ID: 27986552
[TBL] [Abstract][Full Text] [Related]
8. Enhanced mucosal and systemic immune responses obtained by porous silica nanoparticles used as an oral vaccine adjuvant: effect of silica architecture on immunological properties.
Wang T; Jiang H; Zhao Q; Wang S; Zou M; Cheng G
Int J Pharm; 2012 Oct; 436(1-2):351-8. PubMed ID: 22721849
[TBL] [Abstract][Full Text] [Related]
9. CAF01 liposomes as a mucosal vaccine adjuvant: In vitro and in vivo investigations.
Christensen D; Foged C; Rosenkrands I; Lundberg CV; Andersen P; Agger EM; Nielsen HM
Int J Pharm; 2010 May; 390(1):19-24. PubMed ID: 19879346
[TBL] [Abstract][Full Text] [Related]
10. Mannosylated niosomes as adjuvant-carrier system for oral genetic immunization against hepatitis B.
Jain S; Singh P; Mishra V; Vyas SP
Immunol Lett; 2005 Oct; 101(1):41-9. PubMed ID: 15869802
[TBL] [Abstract][Full Text] [Related]
11. In vivo investigation of twin-screw extruded lipid implants for vaccine delivery.
Even MP; Young K; Winter G; Hook S; Engert J
Eur J Pharm Biopharm; 2014 Jul; 87(2):338-46. PubMed ID: 24607791
[TBL] [Abstract][Full Text] [Related]
12. Mannosylated niosomes as adjuvant-carrier system for oral mucosal immunization.
Jain S; Vyas SP
J Liposome Res; 2006; 16(4):331-45. PubMed ID: 17162576
[TBL] [Abstract][Full Text] [Related]
13. Synthesis of a novel kind of carbon nanoparticle with large mesopores and macropores and its application as an oral vaccine adjuvant.
Wang T; Zou M; Jiang H; Ji Z; Gao P; Cheng G
Eur J Pharm Sci; 2011 Dec; 44(5):653-9. PubMed ID: 22064451
[TBL] [Abstract][Full Text] [Related]
14. Enhanced non-inflammasome mediated immune responses by mannosylated zwitterionic-based cationic liposomes for HIV DNA vaccines.
Qiao C; Liu J; Yang J; Li Y; Weng J; Shao Y; Zhang X
Biomaterials; 2016 Apr; 85():1-17. PubMed ID: 26851653
[TBL] [Abstract][Full Text] [Related]
15. New generation of mucosal adjuvants for the induction of protective immunity.
Yuki Y; Kiyono H
Rev Med Virol; 2003; 13(5):293-310. PubMed ID: 12931340
[TBL] [Abstract][Full Text] [Related]
16. Development and characterization of chitosan coated poly-(ɛ-caprolactone) nanoparticulate system for effective immunization against influenza.
Gupta NK; Tomar P; Sharma V; Dixit VK
Vaccine; 2011 Nov; 29(48):9026-37. PubMed ID: 21939718
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of monophosphoryl lipid A as adjuvant for pulmonary delivered influenza vaccine.
Patil HP; Murugappan S; ter Veer W; Meijerhof T; de Haan A; Frijlink HW; Wilschut J; Hinrichs WL; Huckriede A
J Control Release; 2014 Jan; 174():51-62. PubMed ID: 24269505
[TBL] [Abstract][Full Text] [Related]
18. Potentiation of pH-sensitive polymer-modified liposomes with cationic lipid inclusion as antigen delivery carriers for cancer immunotherapy.
Yoshizaki Y; Yuba E; Sakaguchi N; Koiwai K; Harada A; Kono K
Biomaterials; 2014 Sep; 35(28):8186-96. PubMed ID: 24969637
[TBL] [Abstract][Full Text] [Related]
19. Mucosal and systemic immune responses by intranasal immunization using archaeal lipid-adjuvanted vaccines.
Patel GB; Zhou H; Ponce A; Chen W
Vaccine; 2007 Dec; 25(51):8622-36. PubMed ID: 17959279
[TBL] [Abstract][Full Text] [Related]
20. M-cell targeted polymeric lipid nanoparticles containing a Toll-like receptor agonist to boost oral immunity.
Ma T; Wang L; Yang T; Ma G; Wang S
Int J Pharm; 2014 Oct; 473(1-2):296-303. PubMed ID: 24984067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
